表紙
市場調查報告書

高度神經膠質瘤:市場分析,流行病學,七個主要國家的預測

High-Grade Glioma - Market Insights, Epidemiology and Market Forecast - 2030

出版商 DelveInsight Business Research LLP 商品編碼 948130
出版日期 內容資訊 英文 200 Pages
商品交期: 最快1-2個工作天內
價格
高度神經膠質瘤:市場分析,流行病學,七個主要國家的預測 High-Grade Glioma - Market Insights, Epidemiology and Market Forecast - 2030
出版日期: 2020年07月01日內容資訊: 英文 200 Pages
簡介

高級神經膠質瘤(HGG)是神經膠質瘤快速發展的中樞神經系統(CNS)腫瘤。源於腦和脊髓中轉化細胞的實體瘤,也被稱為原發性中樞神經系統腫瘤,因為它們直接源自中樞神經系統。 HGG可以發生在中樞神經系統的不同部位,但最常見的是發生在大腦和腦幹的上皮區。 HGG約佔兒童和青少年中樞神經系統腫瘤的15-20%,每年每100萬兒童中有5至10個發生率。 HGG的治療通常是外科手術,化學療法,放射療法和立體定向放射外科手術的結合,其主要重點是外科手術,但進展很快,以至於很難完全清除。

本報告是對七個主要國家(美國,日本,德國,西班牙,意大利,法國和英國)的HGG相關市場的調查,市場概況,流行病學和患者人數,按國家/地區分類的流行病學,治療它提供有關法律,市場增長動力和障礙以及未滿足需求的信息。

內容

第1章主要發現

第2章市場概述

第3章疾病的背景和概述

  • 簡介
  • 類型
  • 原因
  • 風險因素
  • 體徵和症狀
  • 病理生理學
  • HGG患者生物標誌物
  • 診斷
    • 神經系統檢查
    • 血管造影
    • 磁共振成像(MRI)和計算機斷層掃瞄(CT)
    • 灌注MRI
    • MR光譜
    • 組織學診斷
    • 手術活檢
  • 神經膠質瘤的診斷算法
  • 歐洲神經腫瘤學會(EANO)成人星形膠質細胞和少突膠質細胞瘤診斷指南

第4章流行病學和患者人數

  • 主要發現

高度惡性膠質瘤的7 MM總事件患者人數

第5章主要7個國家的流行病學

  • 美國
  • 5個歐盟國家
    • 德國
    • 法國
    • 意大利
    • 西班牙
    • 英國
  • 日本

第6章治療

  • 手術
  • 放療
  • 膠質母細胞瘤的化學療法
  • 間變性膠質瘤的化學療法
  • 聯合化療
    • 替莫唑胺
    • 血管生成抑製劑
  • 分子靶向治療和其他策略
  • 用藥物治療症狀
  • DIPG的新療法
    • 後生療法
    • 免疫療法
    • 納米顆粒輸送系統

第7章處理算法

第8章《國家綜合癌症網絡(NCCN)治療指南》

  • 未分化的神經膠質瘤/膠質母細胞瘤治療指南

第9章歐洲神經腫瘤學會(EANO)成人星形膠質細胞和少突膠質瘤治療指南

  • 預後因素
  • 外科治療
  • 放療
  • 藥物治療
  • 其他治療
  • 監測和跟進

第10章成年膠質母細胞瘤:關於神經腫瘤學會(SNO)和歐洲神經腫瘤學會(EANO)當前管理和未來方向的共識性回顧

  • 醫療管理和支持治療
  • 標準治療
  • 手術管理
  • 放療注意事項
  • 膠質母細胞瘤復發的情況

第11章,西班牙神經疾病研究小組(GEINO)治療指南

第12章認證機構

第13章HGG註冊中心

第14章未支持的需求

第15章投放市場的藥物

  • Avastin:Genentech
  • Temodar/Temodal:Merck

第16章新藥

  • Eflornithine + Lomustine: Orbus Therapeutics
  • Ofranergene obadenovec(VB-111):VBL Therapeutics
  • Trans Sodium Crocetinate: Diffusion Pharmaceuticals
  • Regorafenib : Bayer
  • Durvalumab (MEDI4736): MedImmune
  • Tasadenoturev (DNX-2401): DNAtrix
  • ONC 201: Oncoceutics
  • Selinexor (KPT-330): Karyopharm Therapeutics
  • VBI -1901: VBI Vaccines
  • Paxalisib (GDC-0084): Kazia Therapeutics
  • AV -GBM-1: Aivita Biomedical
  • MDNA 55: Medicenna Therapeutics
  • VAL -083 (Dianhydrogalactitol): DelMar Pharmaceuticals
  • Pomalidomide : Bristol-Myers Squibb
  • LP 561A1 (2-OHOA): Laminar Pharmaceuticals
  • ITI -1000 (pp65 DC Vaccine): Immunomic Therapeutics
  • INO -5401+ INO-9012+ Cemiplimab (REGN2810): Inovio Pharmaceuticals

第17章7個主要國家的市場分析

  • 主要發現
  • 7個主要國家的市場規模

第18章美國市場展望

  • 美國市場規模
  • 5個歐盟國家
    • 德國
    • 法國
    • 意大利
    • 西班牙
    • 英國
  • 日本

第19章促進市場增長的因素

第20章市場增長的阻礙因素

第21章主要意見領袖的觀點

第22章病例報告

第23章SWOT分析

第24章附錄

  • 參考
  • 調查方法

第25章:DelveInsight服務內容

第26章免責聲明

第27章:關於Delve Insight

目錄
Product Code: DIMI1004

DelveInsight's 'High-grade Glioma (HGG) - Market Insights, Epidemiology and Market Forecast - 2030' report delivers an in-depth understanding of the High-grade Glioma (HGG), historical and forecasted epidemiology as well as the High-grade Glioma (HGG) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The High-grade Glioma (HGG) market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7 MM High-grade Glioma (HGG) market size from 2017-2030. The report also covers current High-grade Glioma (HGG) treatment practices/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered:

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

High-grade Glioma (HGG) Disease Understanding and Treatment Algorithm

High-grade Glioma (HGG) Overview

Highly malignant or high-grade gliomas (HGG) are tumors of the central nervous system (CNS), wherein high-grade means that the glioma is growing rapidly. They are solid tumors arising from transformed cells of the brain and/or the spinal cord. Since they directly originate from the CNS, they are also called primary CNS tumors, thereby differentiating them from malignant tumors of other organs that have spread (metastasized) to the CNS. HGG can occur in different parts of the central nervous system, and they can affect children of any age. The tumors most often originate in the supratentorial region of the brain and the brain stem; HGG originating from the supratentorial region are often called supratentorial HGG.

A glioma is a name for tumors of the glial cells, which are the supporting cells of the nervous system. Gliomas are classified based on the type of glial cells involved in the tumor as well as tumor's genetic features. The World Health Organization (WHO) classification of CNS tumors is the most widely accepted system for classifying CNS tumors and was based on the histological characteristics of the tumor. As per the WHO classification system, grade III tumours (i.e. anaplastic astrocytoma, anaplastic oligoastrocytoma and anaplastic oligodendroglioma), grade IV tumours (i.e. Glioblastoma) and diffuse midline gliomas (DMG), H3K27M-mutant are considered to be high-grade gliomas (HGG).

HGGs account for approximately 15-20 % of CNS tumors in children and adolescents. They appear in all age groups, yet, children aged younger than three years are rarely affected. Each year, about 60-80 children and adolescents younger than 15 years are newly diagnosed with an HGG, which corresponds to an incidence rate of 5-10 new diagnoses/1, 000, 000 children/year. HGGs affect both boys and girls almost equally, and its symptoms vary depending on which area of the brain is affected.

Glial cells are the cells that among other functions, provide support and protection for the brain's nerve cells (neurons). It is known so far that children with certain inherited diseases (such as Li-Fraumeni syndrome, von Hippel-Lindau Syndrome or Turcot syndrome) have a higher risk of developing HGGs than their healthy peers. Besides, it has been shown that malignant glial cell transformation can be associated with genetic alterations and/or chromosomal aberrations in these cells. Such alterations may not be inherited but develop early in childhood. Also, irradiation of the skull (cranial irradiation), for example, during treatment of leukaemia or retinoblastoma, a malignant tumor of the eye, increases the risk of developing a CNS tumor. Most certainly, HGG is caused by a specific combination of many genetic and also environmental factors.

High-grade Glioma (HGG) Diagnosis

The initial diagnostic procedures for a young patient presenting with a suspected CNS tumor at a childhood cancer center include another assessment of the patient's history, a thorough physical/neurological exam and imaging diagnostic, such as magnetic resonance imaging (MRI). The MRI is needed to determine the tumor's localization, size, and demarcation from the surrounding brain (or spinal cord) tissue. In children with a suspected tumor of the visual tract, an assessment by an experienced eye specialist (ophthalmologist) is recommended.

For most patients, the final diagnosis is backed up by a microscopic (histological) examination of tumor tissue that has been neurosurgically removed (biopsy). Children with pontine glioma usually do not undergo neurosurgery, since the risk to cause further damage to this highly vulnerable CNS region is high. Besides, HGGs of the pons can usually be identified by experienced pediatric neuroradiologists based on characteristic MRI-features of these tumors.

Diagnostic procedures required for a definite diagnosis of HGG:

  • Imaging studies require a whole-brain scan, which can be done using MRI or CT. Both tests provide a very detailed image of the brain. Usually, a contrast dye is also given through a vein for the CT or MRI to visualize the brain better. However, a CT or MRI cannot determine for sure if a mass is a brain tumor.
  • The only way to determine the type of tumor with certainty is for a neurosurgeon to remove a piece of the tumor during surgery (resection), which can then be studied under a microscope.
  • A biopsy may be done without a larger surgery; this approach is preferred if the tumor is located within a critical area of the brain or if the patient is too sick for surgery. In these circumstances, a procedure called a stereotactic needle biopsy is used to take a sample of the tumor by inserting a needle through the skull into the brain itself.

High-grade Glioma (HGG) Treatment

Treatment for HGG usually includes a combination of surgery, chemotherapy, radiation, or stereotactic radiosurgery. Surgery is usually one of the most important aspects of treatment, although rarely used alone. Since HGGs develop very rapidly, they are often difficult to remove in their entirety. Therefore, surgery is performed to achieve a maximum safe resection - removing as much of the tumor as possible while preserving the patient's brain function and sparing healthy tissues. Residual cancer cells can be targeted with additional treatments, such as chemotherapy or radiation therapy, after surgery. Radiation therapy and chemotherapy usually follow surgery once the diagnosis or name of the tumor is determined. These treatments are called adjuvant treatments. Because this multispeciality approach can cause several side effects, steroids are often provided as another essential part of HGG treatment, used to help alleviate the side effects of other therapies.

Temozolomide is the standard treatment for adult patients with HGG, but there is no standard chemotherapy backbone that is universally acknowledged in the setting of pediatric HGG. For DIPG in particular, there is no established role for chemotherapy, and radiation is the standard treatment. However, it is mostly palliative in nature, with <10% of children surviving beyond 2 years, despite the majority showing transient improvement in neurologic symptoms following radiotherapy.

High-grade Glioma (HGG) Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Incident Population of High-grade Glioma (HGG), Total Incident Population of Diffuse Midline Glioma (DMG), Total Incident Population of Diffuse Midline Glioma With H3K27 Mutation and Gender-specific Incidence of High-grade Glioma (HGG) in the 7 MM market covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2017-2030.

Key Findings

This section provides glimpse of the High-grade Glioma (HGG) epidemiology in the 7 MM.

  • The total incident population of High-grade Glioma in the 7 major markets was found to be 32,444 in 2017. In case of High-grade Glioma patients in the United States, the incident cases were estimated to be 16,295 in 2017.
  • There are three main types of High-grade Gliomas that are considered in this report: Anaplastic Astrocytoma (WHO Grade III tumor), Glioblastoma (WHO Grade IV tumor) and Diffuse Midline Glioma (WHO Grade IV tumor), where the majority of cases were found to be of glioblastomas that develop rapidly de novo, without clinical or histological evidence of a less malignant precursor lesion.
  • Incidence of Diffuse Midline Glioma with H3K27 Mutation has been considered in this report as well. The highest incidence of H3K27 mutants were found in pediatric population which was estimated to be 303 in 2017 in the United States. However, the incident population of H3K27 mutants in adult population was found to be 204 in 2017 in the United States.
  • Japan accounted for 2,519 incident cases of High-grade Glioma in 2017, which is expected to increase in the forecast period 2020-2030.

Country Wise- High-grade Glioma (HGG) Epidemiology

The epidemiology segment also provides the High-grade Glioma (HGG) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

High-grade Glioma (HGG) Drug Chapters

The drug chapter segment of the High-grade Glioma (HGG) report encloses the detailed analysis of High-grade Glioma (HGG) marketed drugs and mid and late stage pipeline drugs. It also helps to understand the High-grade Glioma (HGG) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details of each included drug and the latest news and press releases.

High-grade Glioma (HGG) Marketed Drugs

  • Avastin: Genentech
  • Temodar/Temodal: Merck
  • High-grade Glioma (HGG) Emerging Drugs
  • Eflornithine + Lomustine: Orbus Therapeutics

Eflornithine (α-difluoromethylornithine or DFMO) is an orally bioavailable small molecule. Eflornithine is an irreversible inhibitor of ornithine decarboxylase (ODC) that presents a cytostatic effect in rapidly dividing cells. ODC is a key enzyme in the first step of the synthesis of polyamines, converting ornithine to putrescine and it is known that ODC is up-regulated in certain types of cancer. Cell studies have demonstrated that polyamines are important for stabilizing DNA structure, the DNA double strand-break repair pathway and as antioxidants. Further evidence points to putrescine being important to the function of RNA and transcription as well and underpins its importance as an essential enzyme for cell growth. In addition, polyamines also upregulate gap junction genes and downregulate tight junction genes. Both of these functions are important as gap junction genes are involved in communication between carcinogenic cells and tight junction genes act as tumour suppressors. Therefore by inhibiting ODC enzyme, eflornithine slows or delays tumour growth, and has shown activity in certain cancers, including anaplastic astrocytoma (AA). Eflornithine has already been approved by the FDA in intravenous form to treat patients with African trypanosomiasis (sleeping sickness) and was subsequently approved by FDA in a topical form to treat patients with excessive facial hair, or hirsutism.

  • Product detail in the report…
  • Ofranergene obadenovec (VB-111): VBL Therapeutics

Ofranergene obadenovec (VB-111) is a first-in-class, targeted anticancer gene-therapy agent that is being developed VBL Therapeutics to treat a wide range of solid tumors such as GBM. It is a non-replicating adenovirus 5 (Ad-5, El-deleted) carrying a proapoptotic human Fas-chimera transgene that targets angiogenic blood vessels and leads to vascular disruption. In patients, improvement has been experienced in post-treatment fever suggesting that VB-111's mode of action involves induction of a tumor-directed immune response. This mechanism retains activity regardless of baseline tumor mutations or the identity of the pro-angiogenic factors secreted by the tumor. VB-111 is the first agent, based on transcriptional targeting of tumor endothelium, to be assessed in a clinical trial. The drug is being investigated using VBL's proprietary Vascular Targeting System (VTS) platform Technology to target endothelial cells in the tumor vasculature for cancer therapy, which is conveniently administered as an IV infusion once every 2 months.

  • Product detail in the report…
  • Trans Sodium Crocetinate: Diffusion Pharmaceuticals

Trans Sodium Crocetinate (TSC), being investigated by Diffusion Pharmaceuticals, is a first-in-class small molecule that, by its novel proprietary mechanism, safely reoxygenates oxygen-deprived tissue. It can act alone or with other treatments and presents opportunities in unmet medical needs across several markets. It can be used to enhance the cancer-killing power of radiation and chemotherapy for treating patients with GBM. TSC counteracts tumor hypoxia and therefore treatment-resistance by safely reoxygenating tumor tissue, thus enhancing tumor kill and potentially prolonging patients' life expectancy. Oxygen levels of normal tissue remain unaffected upon administration of TSC, thereby avoiding the introduction of harmful side effects.

  • Product detail in the report…
  • Regorafenib: Bayer

Regorafenib is an oral multi-kinase inhibitor that potently blocks multiple protein kinases involved in tumor angiogenesis (VEGFR1, -2, -3, TIE2), oncogenesis (KIT, RET, RAF-1, BRAF), metastasis (VEGFR3, PDGFR, FGFR) and tumor immunity (CSF1R). It is an inhibitor of multiple membrane-bound and intracellular kinases involved in normal cellular functions and pathologic processes such as oncogenesis, tumor angiogenesis, and maintenance of the tumor microenvironment.

  • Product detail in the report…
  • Durvalumab (MEDI4736): MedImmune

Durvalumab is an investigational human monoclonal antibody directed against the programmed cell death ligand 1 (PD-L1) protein in development by MedImmune. Signals from PD-L1 help tumors avoid detection by the immune system. Durvalumab blocks these signals, countering the tumor's immune-evading strategies. The antibody belongs to an emerging class of immunotherapies commonly referred to as checkpoint inhibitors; because they remove checks, the body places on immune activation. The mechanism of action of Durvalumab includes PD-L1 expression on tumor cells and tumor-associated immune cells in the tumor microenvironment that can be induced by inflammatory signals and cytokines. PD-L1 blocks T-cell function and activation by interacting with PD-1 and CD80 (B7.1) and reduces cytotoxic T-cell activity, proliferation, and cytokine production.

  • Tasadenoturev (DNX-2401): DNAtrix

DNX-2401, explored by DNAtrix, is oncolytic immunotherapy designed to fulfill the dual requirements of high potency and safety. In order to achieve this, two stable genetic changes in the adenovirus genome were engineered that cause it to replicate selectively in retinoblastoma (Rb) pathway deficient cells and infect tumor cells efficiently. Results from preclinical and clinical studies indicate that DNX-2401 replicates in human tumors, elicits tumor necrosis, triggers intratumoral immune cell infiltration and can lead to long term tumor destruction.

  • ONC201: Oncoceutics

A novel therapeutic intervention of Imipridone class is in development by Oncoceutics, i.e., ONC201, which is a highly selective antagonist of dopamine receptor D2 (DRD2) and ClpP agonist that can penetrate the blood-brain-barrier effectively. ONC201 engages proven anticancer pathways that lead to apoptosis in cancer cells. It is a small molecule originally identified as TNF-related apoptosis-inducing ligand (TRAIL)-inducing compound. It has a unique ability to induce expression of both pro-death ligand TRAIL and its receptor DR5 through the engagement of the cellular integrated stress response (ISR) pathway. ONC201 has demonstrated single-agent efficacy in eliminating cancer stem cells CSCs in glioblastoma, colorectal, and prostate cancer models.

  • Selinexor (KPT-330): Karyopharm Therapeutics

Selinexor (KPT-330) is a first-in-class, oral Selective Inhibitor of Nuclear Export/SINE compound in development by Karyopharm Therapeutics. It functions by binding with and inhibiting the nuclear export protein XPO1 (also called CRM1), leading to the accumulation of tumor suppressor proteins in the cell nucleus, which subsequently reinitiates and amplifies their tumor suppressor function; this is supposed to lead to the selective induction of apoptosis in cancer cells, while largely sparing normal cells. XPO1 is a nuclear exporter protein, which contains a pocket where nuclear proteins can bind. When complexed with these proteins and Ran, activated through guanosine triphosphate (GTP) binding, the XPO1-protein-Ran-GTP complex can exit the nucleus through a nuclear pore. Once outside, GTP is hydrolyzed, and the complex dissociates. The inhibition of this process in cancer cells allows the targets of XPO1, many of which are tumor suppressors, to collect in the nucleus and result in increased transcription of tumor suppressor genes.

  • VBI-1901: VBI Vaccines

VBI-1901 is a cancer vaccine that VBI Vaccines has designed to treat glioblastoma multiforme and medulloblastoma, which are two types of brain tumors. It is designed to kill glioblastoma and medulloblastoma tumor cells infected with cytomegalovirus or CMV. While the immune system already targets cells infected by viruses, VBI-1901's goal is to boost their immune response such viruses. CMV inside tumor cells generate proteins called viral antigens that travel to the cells' surface. It is developed in a way to coax the body to produce antibodies and white blood cells that can kill tumor cells with these antigens. The vaccine does not contain the live virus but consists of tiny particles, called envelopes that contain two kinds of CMV proteins. The particles themselves cannot cause an infection. The immune system recognizes the CMV-generated proteins as foreign to the body and mounts a response against them. Because the proteins are on the surface of tumor cells, the immune system eliminates the tumor cells, too. VBI-1901 also includes a protein called granulocyte-macrophage colony-stimulating factor that gives the vaccine more strength. It spurs its ability to trigger an immune response by attracting immune dendritic cells to the site where the vaccine is injected.

  • Paxalisib (GDC-0084): Kazia Therapeutics

GDC-0084 inhibits the PI3K pathway that is thought to be critical to the development of certain kinds of tumors. GDC-0084 is currently involved in five clinical trials examining the drug in a range of forms of brain cancer, including glioblastoma, DIPG and breast cancer brain metastases (BCBM). The phosphoinositide-3-kinase (PI3K) signalling pathway is one of the central control mechanisms for cells in the human body, which appears to be disordered in more than 85% of cases of glioblastoma. Therefore, this appears to be a high-potential target for new glioblastoma therapies. Paxalisib is a potent inhibitor of the PI3K pathway and is distinguished by its ability to cross the blood-brain barrier (BBB), which prevents many drugs from fully affecting brain tissues.

  • AV-GBM-1: Aivita Biomedical

AV-GBM-1 is a novel immunotherapy consisting of autologous dendritic cells loaded with autologous tumor antigens derived from self-renewing tumor-initiating cells derived from cultured autologous glioblastoma multiforme (GBM) tumor cells, with potential immunostimulatory and antineoplastic activities. The treatment is administered in a series of subcutaneous injections as adjunctive therapy. It is uniquely pan-antigenic, targeting multiple antigens on autologous tumor-initiating cells responsible for the rapid growth of the disease and resistance to standard therapy. Upon administration, the autologous TAA-loaded DCs AV-GBM-1 expose the immune system to the GBM neoantigens, which results in a cytotoxic T-lymphocyte (CTL)-mediated immune response against the autologous GBM cells leading to GBM cell lysis.

High-grade Glioma (HGG) Market Outlook

High Grade Gliomas (HGGs) are the most aggressive cancer that begins within the brain. It is the most frequently occurring type of primary tumors of the central nervous system (CNS) mostly in adults, and its poor prognosis has not been significantly improved even though the innovative diagnostic strategies and new therapies have been developed. HGGs [glioma grade III/IV according to the World Health Organization (WHO) classification] are the most common primary malignant brain tumors in adults. At present, the standard therapy consists of maximal safe surgical resection followed by local brain radiotherapy with concurrent and adjuvant temozolomide (TMZ) chemotherapy. Recurrence of HGG appears to be unavoidable.

HGGs are very difficult tumors to treat due to the problems in completely removing the tumor and their resistance to radiotherapy and chemotherapy. As there is no ideal treatment, therefore it is quite challenging as some cells may respond well to certain therapies, while others may not be affected at all. Because of this, the treatment plan for HGGs may combine several approaches. The treatment often comprises a combination of several therapies, including surgery, chemotherapy, radiation, or stereotactic radiosurgery followed by the additional/adjuvant treatments, such as chemotherapy or radiation therapy, after surgery. Treatment is palliative and may include surgery, radiation therapy and/or chemotherapy. The best treatment options for each person depends on many factors like the size and location of the tumor, the extent to which the tumor has grown into the surrounding normal brain tissues, and the affected person's age and overall health. Though, HGG can be bifurcated into anaplastic astrocytomas and GBM but due to lack of ideal therapies the treatment pattern followed for both the types is similar. However, the occurrence of anaplastic astrocytomas are much lower than GBM.

Key Findings

This section includes a glimpse of the High-grade Glioma (HGG) 7 MM market.

  • The United States accounts for the largest market size of High-grade Glioma (HGG), in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan, which was estimated to be USD 739 Million in 2017.
  • The market size of HGG in the seven major markets was estimated to be USD 1,152 Million in 2017, which is expected to increase during the forecast period 2020-2030.
  • Expected Launch of potential therapies may increase the market size in the coming years, assisted by an increase in the incident population of HGG. The market is expected to witness a significant positive shift owing to the positive outcomes of the several products during the developmental stage by key players such as Bayer, Diffusion Pharmaceuticals, VBL Therapeutics, AstraZeneca, DNAtrix, DelMar Pharmaceuticals, Oncoceutics, KaryoPharma, VBI Vaccines, Kazia Therapeutics, Aivita Biomedical, Medicenna Therapeutics, Immunomic Therapeutics, Inovio Pharmaceuticals, and Orbus Therapeutics.
  • Among the EU5 countries, Germany had the highest market size with USD 85 Million in 2017, while Spain had the lowest market size in 2017 with USD 42 Million, which is expected to increase during the forecast period 2020-2030.
  • The market size of HGG in Japan was estimated to be USD 65 Million in 2017.

High-grade Glioma (HGG) Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the High-grade Glioma (HGG) market or expected to get launched in the market during the study period 2017-2030. The analysis covers High-grade Glioma (HGG) market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

High-grade Glioma (HGG) Development Activities

The report provides insights into different therapeutic candidates in phase II, and phase III stage. It also analyzes key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing and patent details for High-grade Glioma (HGG) emerging therapies.

Competitive Intelligence Analysis

We perform competitive and market Intelligence analysis of the High-grade Glioma (HGG) market by using various competitive intelligence tools that include-SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report:

  • The report covers the descriptive overview of High-grade Glioma (HGG), explaining its causes, signs and symptoms, pathogenesis and currently available therapies.
  • Comprehensive insight has been provided into the High-grade Glioma (HGG) epidemiology and treatment.
  • Additionally, an all-inclusive account of both the current and emerging therapies for High-grade Glioma (HGG) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
  • A detailed review of High-grade Glioma (HGG) market; historical and forecasted is included in the report, covering the 7 MM drug outreach.
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7 MM High-grade Glioma (HGG) market.

Report Highlights:

  • In the coming years, High-grade Glioma (HGG) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence High-grade Glioma (HGG) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • The report contains Gender-specific prevalence of HGG in the 7MM, wherein males are found to suffer more as compared to females.
  • Report also covers Incident Population of Diffuse Midline Glioma, including both adult and pediatric population of HGG.
  • DelveInsight has also estimated Incident Population of Diffuse Midline Glioma With H3K27 Mutation, including both adult and pediatric population of HGG. It was found that H3K27 mutation is more prevalent in adult DMG patients than in pediatric DMG patients.
  • The most commonly used chemotherapeutic drug for treating HGG in the United States is temozolomide (Temodar/Temodal; TMZ). It is generally used in combination with radiation therapy.
  • DelveInsight has found that there are certain upcoming therapies targeting specific mutations in HGG patient pool, such as Oncoceutics, MedImmune and DelMar Pharmaceuticals. Oncoceutics is developing ONC201, which is in phase II clinical trial for H3 K27M-mutant glioma and diffuse midline glioma. On the other hand, Durvalumab by MedImmune is also in its phase II trial for newly diagnosed unmethylated MGMT Glioblastoma.

High-grade Glioma (HGG) Report Insights

  • Patient Population
  • Therapeutic Approaches
  • High-grade Glioma (HGG) Pipeline Analysis
  • High-grade Glioma (HGG) Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

High-grade Glioma (HGG) Report Key Strengths

  • Eleven Years Forecast
  • 7 MM Coverage
  • High-grade Glioma (HGG) Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

High-grade Glioma (HGG) Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions

Market Insights:

  • What was the High-grade Glioma (HGG) market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the High-grade Glioma (HGG) total market size as well as market size by therapies across the 7 MM during the forecast period (2020-2030)?
  • What are the key findings pertaining to the market across the 7 MM and which country will have the largest High-grade Glioma (HGG) market size during the forecast period (2020-2030)?
  • At what CAGR, the High-grade Glioma (HGG) market is expected to grow at the 7MM level during the forecast period (2020-2030)?
  • What would be the High-grade Glioma (HGG) market outlook across the 7 MM during the forecast period (2020-2030)?
  • What would be the High-grade Glioma (HGG) market growth till 2030 and what will be the resultant market size in the year 2030?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of High-grade Glioma (HGG)?
  • What is the historical High-grade Glioma (HGG) patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK) and Japan?
  • What would be the forecasted patient pool of High-grade Glioma (HGG) at the 7 MM level?
  • What will be the growth opportunities across the 7 MM with respect to the patient population pertaining to High-grade Glioma (HGG)?
  • Out of the above-mentioned countries, which country would have the highest prevalent population of High-grade Glioma (HGG) during the forecast period (2020-2030)?
  • At what CAGR the population is expected to grow across the 7 MM during the forecast period (2020-2030)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

  • What are the current options for the treatment of High-grade Glioma (HGG) along with the approved therapy?
  • What are the current treatment guidelines for the treatment of High-grade Glioma (HGG) in the US and Europe?
  • What are the High-grade Glioma (HGG) marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
  • How many companies are developing therapies for the treatment of High-grade Glioma (HGG)?
  • How many therapies are developed by each company for the treatment of High-grade Glioma (HGG)?
  • How many emerging therapies are in the mid-stage and late stage of development for the treatment of High-grade Glioma (HGG)?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the High-grade Glioma (HGG) therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for High-grade Glioma (HGG) and their status?
  • What are the key designations that have been granted for the emerging therapies for High-grade Glioma (HGG)?
  • What are the 7MM historical and forecasted market of High-grade Glioma (HGG)?

Reasons to buy:

  • The report will help in developing business strategies by understanding trends shaping and driving the High-grade Glioma (HGG).
  • To understand the future market competition in the asprgillosis market and Insightful review of the key market drivers and barriers.
  • Organize sales and marketing efforts by identifying the best opportunities for High-grade Glioma (HGG) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
  • Organize sales and marketing efforts by identifying the best opportunities for High-grade Glioma (HGG) market.
  • To understand the future market competition in the High-grade Glioma (HGG) market.

Table of Contents

1 Key Insights

2 High -grade Glioma Market Overview at a Glance

  • 2.1 Market Share (%) Distribution of High-grade Glioma in 2017
  • 2.2 Market Share (%) Distribution of High-grade Glioma in 2030

3 High -grade Glioma (HGG): Disease Background and Overview

  • 3.1 Introduction
  • 3.2 Types
  • 3.3 Causes
  • 3.4 Risk Factors
  • 3.5 Signs and Symptoms
  • 3.6 Pathophysiology
  • 3.7 Biomarkers for patients with HGG
  • 3.8 Diagnosis
    • 3.8.1 Neurological Exams
    • 3.8.2 Angiograms
    • 3.8.3 Magnetic resonance imaging (MRI) and computerized Tomography (CT)
    • 3.8.4 Perfusion MRI
    • 3.8.5 MR spectroscopy
    • 3.8.6 Histological Diagnosis
    • 3.8.7 Surgical Biopsy
  • 3.9 Diagnostic Algorithm for Gliomas
  • 3.1 Diagnostic Guidelines for Adult Astrocytic and Oligodendroglial Gliomas by the European Association for Neuro-oncology (EANO)

4 Epidemiology and Patient Population

  • 4.1 Key Findings
  • 4.2

7 MM Total Incident Patient Population of High-grade Glioma

5 Country Wise-Epidemiology of High-grade Glioma (HGG)

  • 5.1 United States
    • 5.1.1 Assumptions and Rationale
    • 5.1.3 Total Incident Population of High-grade Glioma in the United States
    • 5.1.4 Total Incident Population of Diffuse Midline Glioma in the United States
    • 5.1.5 Total Incident Population of Diffuse Midline Glioma with H3K27 Mutation in the United States
    • 5.1.6 Gender -specific Incidence of High-grade Glioma in the United States
  • 5.2 EU 5 Countries
    • 5.2.1 Assumptions and Rationale
  • 5.3 Germany
    • 5.3.1 Total Incident Population of High-grade Glioma in Germany
    • 5.3.2 Total Incident Population of Diffuse Midline Glioma in Germany
    • 5.3.3 Total Incident Population of Diffuse Midline Glioma with H3K27 Mutation in Germany
    • 5.3.4 Gender -specific Incidence of High-grade Glioma in Germany
  • 5.4 France
    • 5.4.1 Total Incident Population of High-grade Glioma in France
    • 5.4.2 Total Incident Population of Diffuse Midline Glioma in France
    • 5.4.3 Total Incident Population of Diffuse Midline Glioma with H3K27 Mutation in France
    • 5.4.4 Gender -specific Incidence of High-grade Glioma in France
  • 5.5 Italy
    • 5.5.1 Total Incident Population of High-grade Glioma in Italy
    • 5.5.2 Total Incident Population of Diffuse Midline Glioma in Italy
    • 5.5.3 Total Incident Population of Diffuse Midline Glioma with H3K27 Mutation in Italy
    • 5.5.4 Gender -specific Incidence of High-grade Glioma in Italy
  • 5.6 Spain
    • 5.6.1 Total Incident Population of High-grade Glioma in Spain
    • 5.6.2 Total Incident Population of Diffuse Midline Glioma in Spain
    • 5.6.3 Total Incident Population of Diffuse Midline Glioma with H3K27 Mutation in Spain
    • 5.6.4 Gender -specific Incidence of High-grade Glioma in Spain
  • 5.7 United Kingdom
    • 5.7.1 Total Incident Population of High-grade Glioma in the United Kingdom
    • 5.7.2 Total Incident Population of Diffuse Midline Glioma in the United Kingdom
    • 5.7.3 Total Incident Population of Diffuse Midline Glioma with H3K27 Mutation in the United Kingdom
    • 5.7.4 Gender -specific Incidence of High-grade Glioma in the United Kingdom
  • 5.8 Japan
    • 5.8.1 Assumptions and Rationale
    • 5.8.2 Total Incident Population of High-grade Glioma in Japan
    • 5.8.3 Total Incident Population of Diffuse Midline Glioma in Japan
    • 5.8.4 Total Incident Population of Diffuse Midline Glioma with H3K27 Mutation in Japan
    • 5.8.5 Gender -specific Incidence of High-grade Glioma in Japan

6 Treatment

  • 6.1 Surgery
  • 6.2 Radiation Therapy
  • 6.3 Chemotherapy for Glioblastoma
  • 6.4 Chemotherapy for Anaplastic Gliomas
  • 6.5 Multiagent Chemotherapy
    • 6.5.1 Temozolomide
    • 6.5.2 Angiogenesis Inhibitors
  • 6.6 Molecular Targeted Therapy and Other Strategies
  • 6.7 Management of Symptoms with Medication
  • 6.8 New Potential Treatments for DIPG
    • 6.8.1 Epigenetic Therapy
    • 6.8.2 Immunotherapy
    • 6.8.3 Nanoparticle Delivery Systems

7 Treatment Algorithm

8 The National Comprehensive Cancer Network (NCCN) Treatment Guidelines for Brain Tumors

  • 8.1 Treatment Guidelines for Anaplastic Gliomas/ Glioblastoma

9 Treatment Guidelines by the European Association for Neuro-oncology (EANO) for Adult Astrocytic and Oligodendroglial gliomas

  • 9.1 Prognostic Factors
  • 9.2 Surgical Therapy
  • 9.3 Radiotherapy
  • 9.4 Pharmacotherapy
  • 9.5 Other therapeutic approaches
  • 9.6 Monitoring and follow-up

10 Glioblastoma in Adults: A Society for Neuro-oncology (SNO) and European Society of Neuro-oncology (EANO) Consensus Review on Current Management and Future Directions

  • 10.1 Medical Management and Supportive Care
  • 10.2 Standard Therapy
  • 10.3 Surgical Management
  • 10.4 Radiotherapy Considerations
  • 10.5 Recurrent Glioblastoma Scenario

11 Treatment Guidelines by the Neuro-oncology Research Spanish Group (GEINO)

12 Recognized Establishments

13 Registries for HGG

14 Unmet Needs

15 Marketed Drugs

  • 15.1 Avastin : Genentech
    • 15.1.1 Drug Description
    • 15.1.2 Regulatory Milestones
    • 15.1.3 Other Development Activities
    • 15.1.4 Safety and Efficacy
    • 15.1.5 Product Profile
  • 15.2 Temodar /Temodal: Merck
    • 15.2.1 Drug Description
    • 15.2.2 Regulatory Milestones
    • 15.2.3 Other Development Activities
    • 15.2.4 Safety and Efficacy
    • 15.2.5 Product Profile

16 Emerging Drugs

  • 16.1 Key Cross Competition
  • 16.2 Other Emerging Therapies in Development for HGG
  • 16.3 Eflornithine + Lomustine: Orbus Therapeutics
    • 16.3.1 Product Description
    • 16.3.2 Clinical Development
    • 16.3.3 Safety and Efficacy
  • 16.4 Ofranergene obadenovec (VB-111): VBL Therapeutics
    • 16.4.1 Product Description
    • 16.4.2 Clinical Development
    • 16.4.3 Safety and Efficacy
  • 16.5 Trans Sodium Crocetinate: Diffusion Pharmaceuticals
    • 16.5.1 Product Description
    • 16.5.2 Clinical Development
    • 16.5.3 Safety and Efficacy
  • 16.6 Regorafenib : Bayer
    • 16.6.1 Product Description
    • 16.6.2 Clinical Development
    • 16.6.3 Safety and Efficacy
  • 16.7 Durvalumab (MEDI4736): MedImmune
    • 16.7.1 Product Description
    • 16.7.2 Clinical Development
    • 16.7.3 Safety and Efficacy
  • 16.8 Tasadenoturev (DNX-2401): DNAtrix
    • 16.8.1 Product Description
    • 16.8.2 Clinical Development
    • 16.8.3 Safety and Efficacy
  • 16.9 ONC 201: Oncoceutics
    • 16.9.1 Product Description
    • 16.9.2 Clinical Development
    • 16.9.3 Safety and Efficacy
  • 16.1 Selinexor (KPT-330): Karyopharm Therapeutics
    • 16.10.1 Product Description
    • 16.10.2 Clinical Development
    • 16.10.3 Safety and Efficacy
  • 16.11 VBI -1901: VBI Vaccines
    • 16.11.1 Product Description
    • 16.11.3 Clinical Development
    • 16.11.4 Safety and Efficacy
  • 16.12 Paxalisib (GDC-0084): Kazia Therapeutics
    • 16.12.1 Product Description
    • 16.12.2 Clinical Development
    • 16.12.3 Safety and Efficacy
  • 16.13 AV -GBM-1: Aivita Biomedical
    • 16.13.1 Product Description
    • 16.13.2 Clinical Development
    • 16.13.3 Safety and Efficacy
  • 16.14 MDNA 55: Medicenna Therapeutics
    • 16.14.1 Product Description
    • 16.14.2 Clinical Development
    • 16.14.3 Safety and Efficacy
  • 16.15 VAL -083 (Dianhydrogalactitol): DelMar Pharmaceuticals
    • 16.15.1 Product Description
    • 16.15.2 Clinical Development
    • 16.15.3 Safety and Efficacy
  • 16.17 Pomalidomide : Bristol-Myers Squibb
    • 16.17.1 Product Description
    • 16.17.2 Clinical Development
    • 16.17.3 Safety and Efficacy
  • 16.18 LP 561A1 (2-OHOA): Laminar Pharmaceuticals
    • 14.16.2 Product Description
    • 14.16.3 Clinical Development
    • 14.16.4 Safety and Efficacy
  • 16.19 ITI -1000 (pp65 DC Vaccine): Immunomic Therapeutics
    • 14.16.5 Product Description
    • 14.16.6 Clinical Development
    • 14.16.7 Safety and Efficacy
  • 16.2 INO -5401+ INO-9012+ Cemiplimab (REGN2810): Inovio Pharmaceuticals
    • 14.16.8 Product Description
    • 14.16.9 Clinical Development
    • 14.16.10 Safety and Efficacy

17 High -grade Glioma: Seven Major Market Analysis

  • 17.1 Key Findings
  • 17.2 Total Market Size of High-grade Glioma in the 7 MM

18 The United States Market Outlook

  • 18.1 United States Market Size
    • 18.1.1 Total Market size of High-grade Glioma in the United States
    • 18.1.2 Market Size of High-grade Glioma by Current Therapies
    • 18.1.3 Market Size of High-grade Glioma by Emerging Therapies
  • 18.2 EU -5 Countries: Market Outlook
  • 18.3 Germany
    • 18.3.1 Total Market size of High-grade Glioma in Germany
    • 18.3.2 Market Size of High-grade Glioma by Current Therapies
    • 18.3.3 Market Size of High-grade Glioma by Emerging Therapies
  • 18.4 France
    • 18.4.1 Total Market Size of High-grade Glioma in France
    • 18.4.2 Market Size of High-grade Glioma by Current Therapies
    • 18.4.3 Market Size of High-grade Glioma by Emerging Therapies
  • 18.5 Italy
    • 18.5.1 Total Market Size of High-grade Glioma in Italy
    • 18.5.2 Market Size of High-grade Glioma by Current Therapies
    • 18.5.3 Market Size of High-grade Glioma by Emerging Therapies
  • 18.6 Spain
    • 18.6.1 Total Market Size of High-grade Glioma in Spain
    • 18.6.2 Market Size of High-grade Glioma by Current Therapies
    • 18.6.3 Market Size of High-grade Glioma by Emerging Therapies
  • 18.7 United Kingdom
    • 18.7.1 Total Market Size of High-grade Glioma in the United Kingdom
    • 18.7.2 Market Size of High-grade Glioma by Current Therapies
    • 18.7.3 Market Size of High-grade Glioma by Emerging Therapies
  • 18.8 Japan : Market Outlook
  • 18.9 Japan Market Size
    • 18.9.1 Total Market Size of High-grade Glioma in Japan
    • 18.9.2 Market Size of High-grade Glioma by Current Therapies
    • 18.9.3 Market Size of High-grade Glioma by Emerging Therapies
  • 18.1 Market Access and Reimbursement
    • 18.10.1 United States
    • 18.10.2 Europe
    • 18.10.3 Japan

19 Market Drivers

20 Market Barriers

21 KOL Reviews

22 Case Reports

  • 22.1 The Mystery of Multiple Masses: A Case of Anaplastic Astrocytoma (United States)
  • 22.2 Glioblastoma and intracranial aneurysms: Case report and review of the literature (United States)
  • 22.3 A New Method for Ethical and Efficient Evidence Generation for Off-label Medication Use in Oncology (A Case Study in Glioblastoma) (United Kingdom)
  • 22.4 Diagnosis and treatment of early-stage glioblastoma (Japan)

23 SWOT Analysis

24 Appendix

  • 24.1 Bibliography
  • 24.2 Report Methodology

25 DelveInsight Capabilities

26 Disclaimer

27 About DelveInsight

List of Tables

  • Table 1: Genetic and epigenetic alterations found in DMG
  • Table 2: Gene mutations, gene polymorphism, gene variants possibly implicated in glioma risk
  • Table 3: Medical conditions and relation to glioma risk
  • Table 4: Prognostic Molecular Markers in Gliomas
  • Table 5: Total Incident Patient Population of High-grade Glioma in the 7 MM (2017-2030)
  • Table 6: Total Incident Population of High-grade Glioma in the United States (2017-2030)
  • Table 7: Total Incident Population of Diffuse Midline Glioma in the United States (2017-2030)
  • Table 8: Total Incident Population of Diffuse Midline Glioma with H3K27 Mutation in the United States (2017-2030)
  • Table 9: Gender-specific Incidence of High-grade Glioma in the United States (2017-2030)
  • Table 10: Total Incident Population of High-grade Glioma in Germany (2017-2030)
  • Table 11: Total Incident Population of Diffuse Midline Glioma in Germany (2017-2030)
  • Table 12: Total Incident Population of Diffuse Midline Glioma with H3K27 Mutation in Germany (2017-2030)
  • Table 13: Gender-specific Incidence of High-grade Glioma in Germany (2017-2030)
  • Table 14: Total Incident Population of High-grade Glioma in France (2017-2030)
  • Table 15: Total Incident Population of Diffuse Midline Glioma in France (2017-2030)
  • Table 16: Total Incident Population of Diffuse Midline Glioma with H3K27 Mutation in France (2017-2030)
  • Table 17: Gender-specific Incidence of High-grade Glioma in France (2017-2030)
  • Table 18: Total Incident Population of High-grade Glioma in Italy (2017-2030)
  • Table 19: Total Incident Population of Diffuse Midline Glioma in Italy (2017-2030)
  • Table 20: Total Incident Population of Diffuse Midline Glioma with H3K27 Mutation in Italy (2017-2030)
  • Table 21: Gender-specific Incidence of High-grade Glioma in Italy (2017-2030)
  • Table 22: Total Incident Population of High-grade Glioma in Spain (2017-2030)
  • Table 23: Total Incident Population of Diffuse Midline Glioma in Spain (2017-2030)
  • Table 24: Total Incident Population of Diffuse Midline Glioma with H3K27 Mutation in Spain (2017-2030)
  • Table 25: Gender-specific Incidence of High-grade Glioma in Spain (2017-2030)
  • Table 26: Total Incident Population of High-grade Glioma in the United Kingdom (2017-2030)
  • Table 27: Total Incident Population of Diffuse Midline Glioma in the United Kingdom (2017-2030)
  • Table 28: Total Incident Population of Diffuse Midline Glioma with H3K27 Mutation in the United Kingdom (2017-2030)
  • Table 29: Gender-specific Incidence of High-grade Glioma in the United Kingdom (2017-2030)
  • Table 30: Total Incident Population of High-grade Glioma in Japan (2017-2030)
  • Table 31: Total Incident Population of Diffuse Midline Glioma in Japan (2017-2030)
  • Table 32: Total Incident Population of Diffuse Midline Glioma with H3K27 Mutation in Japan (2017-2030)
  • Table 33: Gender-specific Incidence of High-grade Glioma in Japan (2017-2030)
  • Table 34: Adjuvant Treatment of HGG based on Age and Karnofsky Performance Status
  • Table 35: Comparison of emerging drugs under development
  • Table 36: Comparison of emerging drugs under development
  • Table 37: Eflornithine + Lomustine, Clinical Trial Description, 2020
  • Table 38: VB-111, Clinical Trial Description, 2020
  • Table 39: Trans Sodium Crocetinate, Clinical Trial Description, 2020
  • Table 40: Regorafenib, Clinical Trial Description, 2020
  • Table 41: Durvalumab, Clinical Trial Description, 2020
  • Table 42: Tasadenoturev (DNX-2401), Clinical Trial Description, 2020
  • Table 43: ONC201, Clinical Trial Description, 2020
  • Table 44: Selinexor (KPT-330), Clinical Trial Description, 2020
  • Table 45: VBI-1901, Clinical Trial Description, 2020
  • Table 46: Paxalisib (GDC-0084), Clinical Trial Description, 2020
  • Table 47: AV-GBM-1, Clinical Trial Description, 2020
  • Table 48: MDNA55, Clinical Trial Description, 2020
  • Table 49: VAL-083 (Dianhydrogalactitol), Clinical Trial Description, 2020
  • Table 50: Pomalidomide (CC-4047), Clinical Trial Description, 2020
  • Table 51: LP561A1 (2-OHOA), Clinical Trial Description, 2020
  • Table 52: pp65 DC Vaccine, Clinical Trial Description, 2020
  • Table 53: INO-5401+ INO-9012+ Cemiplimab (REGN2810), Clinical Trial Description, 2020
  • Table 54: Total 7 Major Market Size of High-grade Glioma in USD Million (2017-2030)
  • Table 55: Total Market Size of High-grade Glioma in the United States, in USD Million (2017-2030)
  • Table 56: Market size of High-grade Glioma by Current Therapies in the United States, in USD Million (2017-2030)
  • Table 57: Market size of High-grade Glioma by Emerging Therapies in the United States, in USD Million (2017-2030)
  • Table 58: Total Market Size of High-grade Glioma in Germany, in USD Million (2017-2030)
  • Table 59: Market size of High-grade Glioma by Current Therapies in Germany, in USD Million (2017-2030)
  • Table 60: Market size of High-grade Glioma by Emerging Therapies in Germany, in USD Million (2017-2030)
  • Table 61: Total Market Size of High-grade Glioma in France, in USD Million (2017-2030)
  • Table 62: Market size of High-grade Glioma by Current Therapies in France, in USD Million (2017-2030)
  • Table 63: Market size of High-grade Glioma by Emerging Therapies in France, in USD Million (2017-2030)
  • Table 64: Total Market Size of High-grade Glioma in Italy, in USD Million (2017-2030)
  • Table 65: Market size of High-grade Glioma by Current Therapies in Italy, in USD Million (2017-2030)
  • Table 66: Market size of High-grade Glioma by Emerging Therapies in Italy, in USD Million (2017-2030)
  • Table 67: Total Market Size of High-grade Glioma in Spain, in USD Million (2017-2030)
  • Table 68: Market size of High-grade Glioma by Current Therapies in Spain, in USD Million (2017-2030)
  • Table 69: Market size of High-grade Glioma by Emerging Therapies in Spain, in USD Million (2017-2030)
  • Table 70: Total Market Size of High-grade Glioma in the United Kingdom, in USD Million (2017-2030)
  • Table 71: Market size of High-grade Glioma by Current Therapies in the United Kingdom, in USD Million (2017-2030)
  • Table 72: Market size of High-grade Glioma by Emerging Therapies in the United Kingdom, in USD Million (2017-2030)
  • Table 73: Total Market Size of High-grade Glioma in Japan, in USD Million (2017-2030)
  • Table 74: Market size of High-grade Glioma by Current Therapies in Japan, in USD Million (2017-2030)
  • Table 75: Market size of High-grade Glioma by Emerging Therapies in Japan, in USD Million (2017-2030)

List of Figures

  • Figure 1: Causes of HGG
  • Figure 2: Symptoms of HGG
  • Figure 3: Diagnostic Algorithm for Gliomas
  • Figure 4: Total Incident Patient Population of High-grade Glioma in the 7 MM (2017-2030)
  • Figure 5: Total Incident Population of High-grade Glioma in the United States (2017-2030)
  • Figure 6: Total Incident Population of Diffuse Midline Glioma in the United States (2017-2030)
  • Figure 7: Total Incident Population of Diffuse Midline Glioma with H3K27 Mutation in the US (2017-2030)
  • Figure 8: Gender-specific Incidence of High-grade Glioma in the United States (2017-2030)
  • Figure 9: Total Incident Population of High-grade Glioma in Germany (2017-2030)
  • Figure 10: Total Incident Population of Diffuse Midline Glioma in Germany (2017-2030)
  • Figure 11: Total Incident Population of DMG with H3K27 Mutation in Germany (2017-2030)
  • Figure 12: Gender-specific Incidence of High-grade Glioma in Germany (2017-2030)
  • Figure 13: Total Incident Population of High-grade Glioma in France (2017-2030)
  • Figure 14: Total Incident Population of Diffuse Midline Glioma in France (2017-2030)
  • Figure 15: Total Incident Population of DMG with H3K27 Mutation in France (2017-2030)
  • Figure 16: Gender-specific Incidence of High-grade Glioma in France (2017-2030)
  • Figure 17: Total Incident Population of High-grade Glioma in Italy (2017-2030)
  • Figure 18: Total Incident Population of Diffuse Midline Glioma in Italy (2017-2030)
  • Figure 19: Total Incident Population of Diffuse Midline Glioma with H3K27 Mutation in Italy (2017-2030)
  • Figure 20: Gender-specific Incidence of High-grade Glioma in Italy (2017-2030)
  • Figure 21: Total Incident Population of High-grade Glioma in Spain (2017-2030)
  • Figure 22: Total Incident Population of Diffuse Midline Glioma in Spain (2017-2030)
  • Figure 23: Total Incident Population of DMG with H3K27 Mutation in Spain (2017-2030)
  • Figure 24: Gender-specific Incidence of High-grade Glioma in Spain (2017-2030)
  • Figure 25: Total Incident Population of High-grade Glioma in the United Kingdom (2017-2030)
  • Figure 26: Total Incident Population of Diffuse Midline Glioma in the United Kingdom (2017-2030)
  • Figure 27: Total Incident Population of DMG with H3K27 Mutation in the UK (2017-2030)
  • Figure 28: Gender-specific Incidence of High-grade Glioma in the United Kingdom (2017-2030)
  • Figure 29: Total Incident Population of High-grade Glioma in Japan (2017-2030)
  • Figure 30: Total Incident Population of Diffuse Midline Glioma in Japan (2017-2030)
  • Figure 31: Total Incident Population of DMG with H3K27 Mutation in Japan (2017-2030)
  • Figure 32: Gender-specific Incidence of High-grade Glioma in Japan (2017-2030)
  • Figure 33: Schematic illustration of potential epigenetic therapies for DIPG
  • Figure 34: Schematic overview of current immunotherapeutic strategies in DIPG
  • Figure 35: NCCN Guidelines for treatment of Anaplastic Gliomas/Glioblastoma
  • Figure 36: NCCN Guidelines for Treatment of Recurrent Anaplastic Gliomas/Glioblastoma
  • Figure 37: Unmet Needs of High-grade Glioma (HGG)
  • Figure 38: Total 7 Major Market Size of High-grade Glioma in USD Million (2017-2030)
  • Figure 39: Total Market Size of High-grade Glioma in the United States, USD Millions (2017-2030)
  • Figure 40: Market size of High-grade Glioma by Current Therapies in the US, in USD Million (2017-2030)
  • Figure 41: Market size of High-grade Glioma by Emerging Therapies in the US, in USD Million (2017-2030)
  • Figure 42: Total Market Size of High-grade Glioma in Germany, USD Million (2017-2030)
  • Figure 43: Market size of High-grade Glioma by Current Therapies in Germany, in USD Million (2017-2030)
  • Figure 44: Market size of High-grade Glioma by Emerging Therapies in Germany, in USD Million (2017-2030)
  • Figure 45: Total Market Size of High-grade Glioma in France, USD Million (2017-2030)
  • Figure 46: Market size of High-grade Glioma by Current Therapies in France, in USD Million (2017-2030)
  • Figure 47: Market size of High-grade Glioma by Emerging Therapies in France, in USD Million (2017-2030)
  • Figure 48: Total Market Size of High-grade Glioma in Italy, USD Million (2017-2030)
  • Figure 49: Market size of High-grade Glioma by Current Therapies in Italy, in USD Million (2017-2030)
  • Figure 50: Market size of High-grade Glioma by Emerging Therapies in Italy, in USD Million (2017-2030)
  • Figure 51: Total Market Size of High-grade Glioma in Spain, USD Million (2017-2030)
  • Figure 52: Market size of High-grade Glioma by Current Therapies in Spain, in USD Million (2017-2030)
  • Figure 53: Market size of High-grade Glioma by Emerging Therapies in Spain, in USD Million (2017-2030)
  • Figure 54: Total Market Size of High-grade Glioma in the United Kingdom, USD Million (2017-2030)
  • Figure 55: Market size of High-grade Glioma by Current Therapies in the UK, in USD Million (2017-2030)
  • Figure 56: Market size of High-grade Glioma by Emerging Therapies in the UK, in USD Million (2017-2030)
  • Figure 57: Total Market Size of High-grade Glioma in Japan, USD Million (2017-2030)
  • Figure 58: Market size of High-grade Glioma by Current Therapies in Japan, in USD Million (2017-2030)
  • Figure 59: Market size of High-grade Glioma by Emerging Therapies in Japan, in USD Million (2017-2030)
  • Figure 60: Market Drivers
  • Figure 61:Market Barriers
  • Figure 62: High Grade Glioma (HGG) SWOT Analysis